Oral vs. Topical Hair Loss Treatments: Evidence, Side Effects and Who Each Suits
In the US, only two medicines are FDA-approved to treat pattern hair loss: oral finasteride 1 mg (Propecia and generics, for men only) and topical minoxidil (OTC foam or solution, with separate men's and women's labeling). Everything else in the oral vs. topical debate, including low-dose oral minoxidil, oral dutasteride and compounded topical finasteride sprays, is off-label or not FDA-approved, so the real choice is between a stronger evidence base and the tradeoffs of each route, not simply a pill vs. a scalp product. Below, each option is matched to what its label or trial actually shows, so you can take specific questions to a clinician.
Updated · By Treatment Comparison Editorial Team · Sources and scope
Sources: DailyMed (NLM): Propecia FDA label · DailyMed (NLM): Minoxidil 5% foam for men, Drug Facts · DailyMed (NLM): Minoxidil 5% foam for women, Drug Facts · MedlinePlus (NIH): MedlinePlus topical minoxidil · MedlinePlus (NIH): MedlinePlus oral minoxidil · MedlinePlus (NIH): MedlinePlus finasteride · DailyMed (NLM): Avodart FDA label · FDA: FDA alert on compounded topical finasteride (2025) · Journal of the European Academy of Dermatology and Venereology: Topical finasteride phase III trial (2022) · Journal of the American Academy of Dermatology: Oral minoxidil safety study (2021)
What each option is approved for
| Option | Route | FDA status for hair loss | Key label limit |
|---|---|---|---|
| Finasteride 1 mg (Propecia, generics) | Oral | Approved | Men only; not shown to work for receding temples |
| Minoxidil 5% foam or solution | Topical | Approved (OTC) | Top of scalp; not for a receding hairline; 18 and older |
| Low-dose oral minoxidil | Oral | Off-label (tablet approved for high blood pressure) | Tablet label warns of chest pain and heart problems |
| Dutasteride | Oral | Off-label (approved for an enlarged prostate) | No blood donation for 6 months after the last dose |
| Compounded topical finasteride | Topical | Not FDA-approved | FDA has received reports of systemic side effects |
Sources: DailyMed (NLM): Propecia FDA label · DailyMed (NLM): Minoxidil 5% foam for men, Drug Facts · DailyMed (NLM): Minoxidil 5% foam for women, Drug Facts · MedlinePlus (NIH): MedlinePlus oral minoxidil · DailyMed (NLM): Avodart FDA label · FDA: FDA alert on compounded topical finasteride (2025)
What the trials and labels actually measured
Oral finasteride has the longest data set. In the vertex trials on the Propecia label, 14% of men on finasteride had further hair loss at 12 months vs. 58% on placebo, and 35% vs. 100% at 5 years. Year-one sexual side effects were low but above placebo: decreased libido 1.8% vs. 1.3% and erectile dysfunction 1.3% vs. 0.7%.
The topical finasteride evidence most often cited is a single 24-week European phase III trial of a 0.25% spray. It beat placebo on hair count (20.2 vs. 6.7 hairs) with much lower blood levels than the tablet. It is a specific product and dose, so it does not prove that a compounded US spray at a different strength performs the same way.
Low-dose oral minoxidil evidence is mostly observational. A large multicenter safety series (1,404 patients, retrospective, no control group) found unwanted hair growth in 15.1% and systemic effects leading 1.2% to stop, with no life-threatening events reported.
Sources: DailyMed (NLM): Propecia FDA label · Journal of the European Academy of Dermatology and Venereology: Topical finasteride phase III trial (2022) · Journal of the American Academy of Dermatology: Oral minoxidil safety study (2021)
Questions to ask the prescriber
- Is my pattern (crown, top of scalp, temples) one the medicine is shown to help?
- Is this option FDA-approved for hair loss, or off-label or compounded?
- For oral minoxidil: do my blood pressure, heart or kidney history rule it out?
- For finasteride or dutasteride: how will this affect my PSA test, and who else in my home could be exposed?
- When will we judge whether it is working, and what happens if I stop?
Sources: DailyMed (NLM): Propecia FDA label · MedlinePlus (NIH): MedlinePlus oral minoxidil · MedlinePlus (NIH): MedlinePlus finasteride · DailyMed (NLM): Avodart FDA label
| Feature | oral treatment | topical treatment |
|---|---|---|
| FDA-approved for hair loss | Finasteride 1 mg only (men only; not indicated for women or children) | Minoxidil 5% foam or solution for men; 5% foam once daily for women |
| Off-label or unapproved options | Low-dose oral minoxidil (approved only as a blood pressure tablet); dutasteride (approved for an enlarged prostate) | Compounded topical finasteride, often mixed with minoxidil (no FDA-approved topical finasteride exists) |
| Labeled routine | Finasteride: one 1 mg tablet daily, with or without food | Men's 5% foam: half a capful twice daily. Women's 5% foam: half a capful once daily |
| Labeled time to results | Finasteride: usually 3 months or more of daily use | Men: may start at 2 months, some need 4. Women: may start at 3 months, some need 6 |
| If you stop | Finasteride label: the effect reverses within 12 months | Drug Facts: hair loss resumes without continued use |
| Main side effects to know | Finasteride: sexual side effects in a small share of trial patients, mood changes reported. Oral minoxidil: unwanted body or facial hair, lightheadedness, fluid retention | Minoxidil: scalp itching, flaking, unwanted facial hair. Compounded topical finasteride: FDA received reports of systemic effects similar to oral finasteride |
| Prescription needed | Yes, for every oral option | No for OTC minoxidil; yes for any compounded finasteride topical |
| Cost drivers | Generic finasteride and generic minoxidil tablets are older generics; total cost also depends on any visit or membership fee | OTC minoxidil is sold at pharmacies without a visit; compounded combination topicals are custom-made and usually priced by the telehealth provider. Check the renewal price, not the first order |
Choose oral treatment if...
Oral treatment may fit men with crown or mid-scalp thinning who want the option with the longest track record against the hormonal cause: in the Propecia trials, 14% of men taking finasteride had further visible hair loss at 12 months vs. 58% on placebo, and the gap held through 5 years. It also suits people who will not keep up a daily scalp routine. The tradeoffs: finasteride is labeled for men only, it lowers PSA (tell whoever orders your prostate tests), and women who are or may become pregnant must not handle crushed or broken tablets. Low-dose oral minoxidil is an off-label use of a blood pressure drug, so it needs a clinician who screens for heart, kidney and blood pressure issues.
Choose topical treatment if...
Topical treatment may fit anyone who wants to start without a prescription, and it is the only FDA-approved route for women: the women's 5% foam is labeled for once-daily use on the top of the scalp. It also suits men who want to avoid a systemic hormone blocker. Know the limits: minoxidil Drug Facts say it is for the top of the scalp and not for a receding hairline or frontal baldness, it is not for people under 18, and you should stop and ask a doctor if you get chest pain, a rapid heartbeat, dizziness or swelling. Compounded topical finasteride is a different product: it needs a prescription, is not FDA-approved, and still reaches the bloodstream.
The Verdict
For men, oral finasteride has the strongest long-term evidence and topical minoxidil is the easiest place to start; some clinicians combine the two because they work by different mechanisms. For women, topical minoxidil is the only FDA-approved option, and oral routes are clinician-supervised and off-label. The middle-ground products, low-dose oral minoxidil and compounded topical finasteride, have real but thinner evidence: a retrospective safety study for the first and one European phase III trial of a specific spray for the second. Treat them as options to discuss with a clinician, not as upgrades.
Frequently Asked Questions
Sources and editorial notes
Approval status, labeled use, time to results and side effects were checked on October 25, 2026 against the Propecia and Avodart labels and minoxidil Drug Facts on DailyMed, MedlinePlus, the FDA's 2025 compounded topical finasteride alert, and the two named studies. This is desk research, not clinical testing or a clinician review; we removed provider price ranges we could not confirm.
Content updated . Source checking is editorial work; it is not a clinical review.
- DailyMed (NLM): PROPECIA (finasteride) tablets: prescribing informationMedical or regulatory reference · Accessed 2026-10-25
- DailyMed (NLM): Minoxidil 5% (for men) topical foam: Drug FactsMedical or regulatory reference · Accessed 2026-10-25
- DailyMed (NLM): Minoxidil 5% (for women) topical foam: Drug FactsMedical or regulatory reference · Accessed 2026-10-25
- MedlinePlus (NIH): Minoxidil TopicalMedical or regulatory reference · Accessed 2026-10-25
- MedlinePlus (NIH): Minoxidil (oral)Medical or regulatory reference · Accessed 2026-10-25
- MedlinePlus (NIH): FinasterideMedical or regulatory reference · Accessed 2026-10-25
- DailyMed (NLM): AVODART (dutasteride) capsules: prescribing informationMedical or regulatory reference · Accessed 2026-10-25
- FDA: FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride productsMedical or regulatory reference · Accessed 2026-10-25
- Journal of the European Academy of Dermatology and Venereology: Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-294Medical or regulatory reference · Accessed 2026-10-25
- Journal of the American Academy of Dermatology: Vano-Galvan S, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651Medical or regulatory reference · Accessed 2026-10-25